The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to the PROTECT-V trial – a platform study investigating UNION’s niclosamide-based treatment candidate for COVID-19 in kidney patients.
Clinical trials granted UPH prioritization by the NIHR are deemed critically important in the fight against COVID-19 and will thus receive infrastructure support allowing expedited recruitment for the study. NIHR is an entity under the Department of Health & Social Care of the UK government.
UPH prioritization will enable streamlined site set up across the UK, and facilitate rapid patient recruitment as a result of NIHR resource and clinical research network support being available.
The PROTECT-V trial is led by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge and involves researchers and patients from across the UK.
For more information visit: UNION Therapeutics
Published March 29 2021
Latest from CCTU
Innovative trial offers hope on World Pancreatic Cancer Day
An early-stage trial, recently opened at Addenbrooke's Hospital, offers new hope tp people with late-stage pancreatic cancer and their families.
…
National Patient Led Research Hub celebrates tenth anniversary
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
